News

Yahoo Finance9mon
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
On Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Hympavzi ... FDA Approves Pfizer's Second Hemophilia Drug With Six Months. Vandana Singh . Mon, Oct 14, 2024, 7:35 AM 2 min read.
Medscape9mon
FDA Approves Pfizer's Hympavzi for Hemophilia A, B - Medscape
FDA Approves Pfizer's Hympavzi for Hemophilia A, B. M. Alexander Otto, PA, MMS. October 11, 2024 . 0. The US Food and Drug Administration (FDA) has approved Hympavzi (marstacimab, ...
Pharm Exec9mon
FDA Approves Pfizer’s Hympavzi for Prophylaxis in Patients with ...
The FDA has approved Pfizer’s Hympavzi (marstacimab-hncq) for routine prophylaxis (RP) in adults and adolescents over 12 years of age with hemophilia A or B without inhibitors. Hympavzi is now the ...
UPI9mon
FDA approves first once-weekly drug treatment regimen for hemophilia
Hympavzi, made by Pfizer, is the first antitissue-factor pathway inhibitor to be approved for the blood-clotting disorder, as well as the first hemophilia drug to offer a once-weekly treatment ...
CBS News2y
FDA approves most expensive drug ever, a $3.5 million-per-dose gene ...
Washington — U.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder. The Food and Drug Administration ...
Business Wire1y
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the ...
CNN2y
FDA approves $3.5 million treatment for hemophilia, now the most ... - CNN
The US Food and Drug Administration on Tuesday approved Hemgenix, a new drug to treat hemophilia. Manufacturer CSL Behring set the price at $3.5 million per treatment, making it the most expensive ...
AOL9mon
FDA Approves Pfizer's Second Hemophilia Drug With Six Months - AOL
On Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients ...
Nasdaq9mon
FDA Approves Pfizer's HYMPAVZI For Hemophilia A And B ... - Nasdaq
FDA Approves Pfizer's HYMPAVZI For Hemophilia A And B Treatment In Adults And Adolescents October 11, 2024 — 11:04 pm EDT Written by RTTNews.com for RTTNews -> ...
Hosted on MSN9mon
FDA approves first once-weekly drug treatment regimen for hemophilia - MSN
Hympavzi, made by Pfizer, is the first antitissue-factor pathway inhibitor to be approved for the blood-clotting disorder, as well as the first hemophilia drug to offer a once-weekly treatment ...
Benzinga.com9mon
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
FDA approves Pfizer’s Hympavzi for routine prophylaxis in hemophilia A and B patients, offering a once-weekly dosing via auto-injector pen. Phase 3 trial showed Hympavzi reduced bleeding rates ...